XTX Topco Ltd Invests $640,000 in Bio-Rad Laboratories, Inc. (NYSE:BIO)

XTX Topco Ltd acquired a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 1,949 shares of the medical research company’s stock, valued at approximately $640,000.

A number of other institutional investors and hedge funds have also bought and sold shares of BIO. Vanguard Group Inc. grew its holdings in shares of Bio-Rad Laboratories by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 1,919,808 shares of the medical research company’s stock valued at $630,676,000 after buying an additional 12,168 shares during the last quarter. Wealthfront Advisers LLC bought a new position in Bio-Rad Laboratories in the 4th quarter valued at approximately $342,686,000. Sei Investments Co. boosted its stake in Bio-Rad Laboratories by 7.5% during the 4th quarter. Sei Investments Co. now owns 271,387 shares of the medical research company’s stock valued at $89,156,000 after purchasing an additional 18,873 shares during the last quarter. Mawer Investment Management Ltd. increased its holdings in shares of Bio-Rad Laboratories by 17.9% in the 4th quarter. Mawer Investment Management Ltd. now owns 256,927 shares of the medical research company’s stock worth $84,403,000 after purchasing an additional 39,042 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Bio-Rad Laboratories by 4.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 191,867 shares of the medical research company’s stock worth $63,030,000 after purchasing an additional 7,552 shares in the last quarter. 65.24% of the stock is currently owned by institutional investors.

Bio-Rad Laboratories Trading Down 2.9 %

Bio-Rad Laboratories stock opened at $238.02 on Friday. Bio-Rad Laboratories, Inc. has a 52-week low of $215.38 and a 52-week high of $387.99. The company has a market cap of $6.67 billion, a P/E ratio of -3.66 and a beta of 1.12. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18. The business has a 50-day simple moving average of $255.62 and a two-hundred day simple moving average of $311.81.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. Analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Wall Street Analysts Forecast Growth

BIO has been the topic of several recent analyst reports. StockNews.com cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, February 17th. Wells Fargo & Company dropped their price target on shares of Bio-Rad Laboratories from $320.00 to $270.00 and set an “equal weight” rating on the stock in a report on Thursday. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $380.20.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.